Tau Capital has published its results for the year to the end of December 2013. These are somewhat academic now but, for what it’s worth, its NAV declined from $0.53 to $0.30. Since the year end its investment in Stopharm has been written down further.
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated